Cernilton® Efficiency and Safety in Treatment of Patients with Chronic Abacterial Prostatitis and BPH Evaluation Recent

Sivkov A.V., Bedretdinova D.A.

Cernilton® Efficiency and Safety in Treatment of Patients with Chronic Abacterial Prostatitis and BPH Evaluation Recent A.V. Sivkov, D.A. Bedretdinova Cernilton® is a medication which active components are microbiologically fermented pollen extract of various plants. Medicine has antiedemic and anti-inflammatory activity, capable to inhibit 5-а reductase thus slowing down prostate cells proliferation. Also improves voiding by а-1 receptors blocking and direct relaxation activity on urethral smooth muscles.

Cernilton® evaluation of efficiency and safety in patients with prostate deceases recent researches reviewed. 60 publications dedicated to this topic were found through MedLine. The earliest one is dated after 1962. Fundamental investigations of Cernilton® mechanism of action were done. Numerous controlled randomized clinical studies with quantity of patients are still going on. Different dosage long term results already published. Due to long-term studies demonstrate continuous efficiency and safety of Cernilton®. This allows to recommend Cernilton® as a supporting and prophylactic medicine. Thereby Cernilton® is highly-effective, safe medication of choice in treatment of patientswith chronic abacterial prostatitis and BPH.

AttachmentSize
Статья в формате PDF214.83 KB